All people over 75 years with a five-year CVD risk of ≥15% should be treated with statins unless specifically contraindicated

Journal of Primary Health Care

Volumn 2, Issue 4, 2010, Pages 330-332

  Wells, Sue ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DRUG CONTRAINDICATION; FEMALE; HUMAN; MALE; QUALITY OF LIFE; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PHYSICIAN'S PRACTICE PATTERNS; QUALITY OF LIFE; RISK ASSESSMENT;

EID: 79952276668     PISSN: 11726164     EISSN: 11726156     Source Type: Journal    
DOI: 10.1071/hc10330     Document Type: Article

References (9)

1. World Health Organization. Global burden of disease. Death and DALY estimates for 2004 by cause for WHO member states. Geneva: World Health Organization; 2009.
2. Chan WC, Wright C, Riddell T, Wells S, Kerr AJ, Gala G, et al. Ethnic and socioeconomic disparities in the prevalence of cardiovascular disease in New Zealand. N Z Med J. 2008;121(1285):11-20.
3. Bekelman DB, Rumsfeld JS, Havranek EP, Yamashita TE, Hutt E, Gottlieb SH, et al. Symptom burden, depression, and spiritual well-being: a comparison of heart failure and advanced cancer patients. J Gen Int Med. 2009;24(5):592-8.
4. Terry DF, Sebastiani P, Andersen SL, Perls TT. Disentangling the roles of disability and morbidity in survival to exceptional old age. Arch Int Med. 2008;168(3):277-83.
5. Yates LB, Djousse L, Kurth T, Buring JE, Gaziano JM. Exceptional longevity in men: modifiable factors associated with survival and function to age 90 years. Arch Int Med. 2008;168(3):284-90.
6. De Ruijter W, Westendorp RGJ, Assendelft WJJ, den Elzen WPJ, de Craen AJM, le Cessie S, et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ. 2009;338:a3083.
7. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78.
8. Packard CJ, Ford I, Robertson M, Shepherd J, Blauw GJ, Murphy MB, et al. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation. 2005;112(20):3058-65.
9. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJM, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol. 2008;51(1):37-45.